Neuraminidase 2 (NEU2), also known as sialidase-2, is a cytosolic glycohydrolytic enzyme responsible for cleaving terminal sialic acid residues from glycoproteins and glycolipids, with substrate specificity favoring alpha-(2→3)-linked sialic acids, such as those found on certain gangliosides like GD1a, GT1B, and GM1. The enzyme belongs to the sialidase family (glycoside hydrolases), is structurally characterized by a six-blade β-propeller fold, and demonstrates substrate recognition via a network of active-site residues. NEU2 is involved in critical cell signaling functions, including platelet activation and aggregation through regulated membrane association and desialylation. Diseases linked to NEU2 encompass viral infection (influenza, due to the relevance of neuraminidases), glycoproteinosis, and altered platelet biology, though therapeutic manipulation in humans remains largely experimental.
Competitive inhibition of sialidase catalytic activity, blocking terminal sialic acid removal. Interference with substrate binding and active site function (as demonstrated for DANA inhibitor)
03
Biological functions
Removes terminal sialic acid residues from glycoproteins and glycolipidsInvolved in catabolism of glycolipids, glycoproteins, and oligosaccharidesCytosolic localization, with roles in cell signaling (especially relating to platelets and membrane dynamics)Recognizes specific sialyl linkages (preferentially alpha-(2→3) sialylated gangliosides GD1a, GT1B, and GM1)Participates in substrate recognition for glycan processing
04
Disease associations
Infection (including Influenza)GlycoproteinosisPlatelet function and aggregation (potential relevance in bleeding and clotting disorders, though no direct disease association indicated)Other: Possibly involved in sialic acid metabolism disorders
05
Safety considerations
Potential concerns if broadly inhibiting sialidases—possible effects on glycoprotein and glycolipid metabolism, platelet activation function, risk of unwanted bleeding or thrombosis via effects on platelet desialylationLack of specific safety data relating to targeted NEU2 inhibition (off-target effects are more commonly discussed for viral neuraminidase inhibitors)
06
Interacting drugs
General neuraminidase inhibitors (e.g., DANA, a NEU-inhibitor shown to affect platelet activation and aggregation)
1 more in the full profile.
07
Biomarkers
Null (no established NEU2-specific biomarkers for patient selection or efficacy monitoring; mentions of platelet surface changes and sialylation, e.g., with RCA-1 binding, but not clinically validated)
Beyond the preview
Go deeper on Neuraminidase 2 (NEU2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuraminidase 2 (NEU2).